Literature DB >> 35549358

Pseudoprogression during Immunotherapy in Metastatic Head and Neck Squamous Cell Carcinoma.

Akshay Bedmutha1, Ashish Kaushal1.   

Abstract

Entities:  

Keywords:  Head and Neck; Metastases; Molecular Imaging-Immunotherapy; PET/CT; Treatment Effect

Mesh：

Substances：

Year:  2022        PMID： 35549358      PMCID： PMC9152687          DOI： 10.1148/rycan.220037

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN： 2638-616X


× No keyword cloud information.
  5 in total

1.  Real-World Pseudoprogression: an Uncommon Phenomenon.

Authors:  Karen L Reckamp
Journal:  J Thorac Oncol       Date:  2018-07       Impact factor: 15.609

2.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

3.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Authors:  F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jeffrey S Weber; Adil Daud; Omid Hamid; Amita Patnaik; Antoni Ribas; Caroline Robert; Tara C Gangadhar; Anthony M Joshua; Peter Hersey; Roxana Dronca; Richard Joseph; Darcy Hille; Dahai Xue; Xiaoyun Nicole Li; S Peter Kang; Scot Ebbinghaus; Andrea Perrone; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2016-03-07       Impact factor: 44.544

4.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Anqin Han; Hui Zhu; Jinming Yu
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.